Pandox, a leading hotel property company operating across Europe, has reported a 15% decline in Q2 profits to £43.3 million. The financial results, announced on 15 July 2026, were dampened by significant derivative losses, offsetting the benefits of its recent acquisition of the Dalata Hotel Group.
The Dalata deal, completed in Q1 2026, has driven growth for Pandox, with revenue up 12% to £434.1 million. However, the loss-making derivatives, valued at £25.6 million, weighed heavily on the company's financial performance.
Pandox's Q2 results show a 3.5% decrease in revenue per available room (RevPAR) across its European portfolio, with the UK experiencing a 4.4% decline. This trend is echoed in the wider UK hotel industry, where RevPAR has fallen by 5.6% year-on-year, according to recent data.
The Bank of England's base rate, currently set at 4.75%, has also had a bearing on the UK hotel sector, with higher borrowing costs weighing on operators' profit margins. Pandox's management has acknowledged the challenges posed by the rising interest rate environment and the ongoing impact of Brexit on the UK hotel market.
As the UK's hotel industry continues to navigate these challenges, investors will be keeping a close eye on Pandox's performance. The company's shares have taken a hit, falling by 8.2% on the London Stock Exchange since the Q2 results announcement.
With the UK's economic uncertainty set to persist, Pandox's ability to adapt to these conditions will be crucial in determining its future success.